Latest Conference Articles

May 18th 2015, 6:54am

AUA Annual Meeting

Brock O'Neil, MD, physician, instructor in urologic surgery, Vanderbilt University, discusses a study that demonstrated evidence of superior quality of life after robotic assisted radical prostatectomy.

May 17th 2015, 2:40pm

AUA Annual Meeting

Since the USPSTF guideline on PSA screening the overall rate of PSA testing decreased by 50% among primary care physicians at Oregon Health & Science University.

May 17th 2015, 2:28pm

AUA Annual Meeting

A urine assay that targets expression of exosomal messenger RNA demonstrated high negative predictive value for high-grade prostate cancer in a study that validates the emerging test as a tool to help determine whether patients need initial biopsies.

May 17th 2015, 11:16am

AUA Annual Meeting

Enzalutamide significantly improved progression-free survival, PSA kinetics, and quality of life compared with bicalutamide in men with castration-resistant prostate cancer.

May 17th 2015, 7:58am

AUA Annual Meeting

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses the association between urinary tract infections (UTI) and worse bladder cancer outcomes in the Medicare population.

May 17th 2015, 5:03am

AUA Annual Meeting

Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the clinical utility of the cell cycle progression (CCP) test in personalizing prostate cancer treatment.

May 16th 2015, 2:37pm

AUA Annual Meeting

As the AS strategy gains a foothold among urologists both here in the US and around the world, a study presented at the 110th Annual Scientific Meeting of the American Urological Association suggests that among men in the US, very few are following the stringent protocol for AS that is recommended by major academic institutions.

May 16th 2015, 1:05pm

AUA Annual Meeting

Use of multiparametric MRI as follow-up to a suggestive PSA test or digital rectal exam reduced prostate biopsies by 73% but identified fewer prostate cancers compared with upfront transrectal ultrasound–guided biopsy, a decision-tree analysis showed.

May 16th 2015, 12:22pm

AUA Annual Meeting

The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association (AUA) Meeting is bringing the discussion into focus.

May 16th 2015, 9:23am

AUA Annual Meeting

Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.

May 16th 2015, 7:23am

AUA Annual Meeting

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado Denver, discusses the differences between an LHRH agonist and a GNRH antagonist.

May 13th 2015, 1:09pm

ASCO Annual Meeting

Adding elotuzumab to lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed/refractory multiple myeloma.

May 13th 2015, 1:06pm

ASCO Annual Meeting

The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.

May 13th 2015, 1:00pm

ASCO Annual Meeting

For those with a history of non-melanoma skin cancer, reducing their risk of recurrence can be as simple as taking the vitamin B3 pill nicotinamide.

May 13th 2015, 1:00pm

ASCO Annual Meeting

Treatment with an intensified chemotherapy regimen was associated with improvements in event-free survival for children with favorable histology Wilms tumor with loss of heterozygosity in chromosomes 1p and 16q.

May 7th 2015, 7:57am

MDS Symposium

Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses deferasirox (Exjade) in iron chelation therapy for patients with myelodysplastic syndromes (MDS).

May 2nd 2015, 11:42am

MDS Symposium

Treatment with the thrombopoietin receptor agonist eltrombopag significantly improved cytopenias and was well-tolerated in patients with low to intermediate-2 risk myelodysplastic syndromes.

May 2nd 2015, 8:05am

MDS Symposium

A biomarker model that incorporates the mutational status of multiple somatic genes could be used to predict response to hypomethylating agents for patients with myelodysplastic syndromes.

May 2nd 2015, 6:44am

MDS Symposium

Serum erythropoietin levels and risk by IPSS were predictive of response to erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.

May 2nd 2015, 5:25am

MDS Symposium

Gail J. Roboz, MD, associate professor of Medicine, director, Leukemia Program, Weill Medical College of Cornell University, New York-Presbyterian Hospital, discusses the growing field of molecular mutations in myelodysplastic syndromes (MDS).